Last updated on August 2018

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Brief description of study

This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.

Clinical Study Identifier: NCT02409342

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GO29431 ...

Tokyo Medical University Hospital; Dept of Surgery
Tokyo, Japan

Reference Study ID Number: GO29431 ...

National Cancer Center Hospital; Thoracic Medical Oncology
Tokyo, Japan